Andreas Engert

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. doi request reprint XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
    A Engert
    Department of Internal Medicine, University Clinic of Cologne, Germany
    Leuk Lymphoma 50:374-9. 2009
  2. doi request reprint Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
    Andreas Engert
    University Hospital of Cologne, Department of Internal Medicine I, Koln, Germany
    Lancet 379:1791-9. 2012
  3. ncbi request reprint Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
    R Schnell
    Klinik I fuer Innere Medizin, Universitaet zu Koeln, 50924 Koeln, Germany
    Ann Oncol 14:729-36. 2003
  4. doi request reprint Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma
    Andreas Engert
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany
    Onkologie 32:599-604. 2009
  5. doi request reprint Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study
    Andreas Engert
    Klinik I fur Innere Medizin, Universitätsklinik Köln, Kerpener Strasse 62, 50931 Koln, Germany
    J Clin Oncol 27:4548-54. 2009
  6. ncbi request reprint Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Germany
    Br J Haematol 122:413-23. 2003
  7. ncbi request reprint Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial
    Andreas Engert
    First Department of Internal Medicine, Coordination Center for Clinical Trials, and Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 25:3495-502. 2007
  8. ncbi request reprint Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study
    Andreas Engert
    Department I of Internal Medicine, University of Cologne, Cologne, Germany
    Haematologica 91:546-9. 2006
  9. ncbi request reprint Recombinant human erythropoietin in oncology: current status and further developments
    A Engert
    Klinik I fur Innere Medizin, Universitätsklinikum Köln, Koln, Germany
    Ann Oncol 16:1584-95. 2005
  10. ncbi request reprint Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group
    Andreas Engert
    Department of Internal Medicine, University of Cologne, Kerpener Str 62, 50924 Cologne, Germany
    J Clin Oncol 23:5052-60. 2005

Detail Information

Publications155 found, 100 shown here

  1. doi request reprint XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
    A Engert
    Department of Internal Medicine, University Clinic of Cologne, Germany
    Leuk Lymphoma 50:374-9. 2009
    ..Treatment with XM02 is as beneficial as filgrastim in ameliorating severe neutropenia and FN in patients with NHL receiving chemotherapy. XM02 is safe and well tolerated in the doses applied in this study...
  2. doi request reprint Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
    Andreas Engert
    University Hospital of Cologne, Department of Internal Medicine I, Koln, Germany
    Lancet 379:1791-9. 2012
    ..We did a prospective randomised clinical trial comparing two reduced-intensity chemotherapy variants with our previous standard regimen. Chemotherapy was followed by PET-guided radiotherapy...
  3. ncbi request reprint Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
    R Schnell
    Klinik I fuer Innere Medizin, Universitaet zu Koeln, 50924 Koeln, Germany
    Ann Oncol 14:729-36. 2003
    ..Both ITs showed potent specific activity against HL cells in vitro and in vivo in animal models, and were subsequently evaluated in phase I/II clinical trials in humans...
  4. doi request reprint Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma
    Andreas Engert
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany
    Onkologie 32:599-604. 2009
    ....
  5. doi request reprint Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study
    Andreas Engert
    Klinik I fur Innere Medizin, Universitätsklinik Köln, Kerpener Strasse 62, 50931 Koln, Germany
    J Clin Oncol 27:4548-54. 2009
    ..The previous analysis with 5 years median follow-up had indicated improved tumor control with BEACOPP escalated. Since the long-term safety and efficacy of this regimen has been debated, we report the 10-year follow-up...
  6. ncbi request reprint Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Germany
    Br J Haematol 122:413-23. 2003
    ..However, there is no evidence that G-CSF/GM-CSF improved CR and OS in this clinical setting...
  7. ncbi request reprint Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial
    Andreas Engert
    First Department of Internal Medicine, Coordination Center for Clinical Trials, and Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 25:3495-502. 2007
    ....
  8. ncbi request reprint Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study
    Andreas Engert
    Department I of Internal Medicine, University of Cologne, Cologne, Germany
    Haematologica 91:546-9. 2006
    ..Toxicities were mostly moderate in intensity. These results support the feasibility of delivering full dose, on schedule BEACOPP-14, chemotherapy with pegfilgrastim support...
  9. ncbi request reprint Recombinant human erythropoietin in oncology: current status and further developments
    A Engert
    Klinik I fur Innere Medizin, Universitätsklinikum Köln, Koln, Germany
    Ann Oncol 16:1584-95. 2005
    ..In addition, very recent results of a Food and Drug Administration meeting on safety and survival of patients treated with erythropoietin are presented...
  10. ncbi request reprint Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group
    Andreas Engert
    Department of Internal Medicine, University of Cologne, Kerpener Str 62, 50924 Cologne, Germany
    J Clin Oncol 23:5052-60. 2005
    ..We thus performed a retrospective analysis using the German Hodgkin's Study Group (GHSG) database to determine clinical risk factors, course of treatment, and outcome in elderly HL patients in comparison with younger adults...
  11. doi request reprint Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial
    Andreas Engert
    University Hospital of Cologne, Department of Internal Medicine, Kerpener Str 62, Cologne, Germany 50924
    J Clin Oncol 28:2239-45. 2010
    ....
  12. ncbi request reprint The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma
    A Engert
    Department I for Internal Medicine, University of Cologne, Germany
    Curr Top Microbiol Immunol 234:13-33. 1998
    ..Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration...
  13. doi request reprint Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
    Andreas Engert
    Department of Internal Medicine, University of Cologne, Cologne, Germany
    N Engl J Med 363:640-52. 2010
    ....
  14. ncbi request reprint [Role of high-dose chemotherapy in hematology and internal medicine/ oncology]
    A Engert
    Klinik I fur Innere Medizin, Universitat zu Koln
    Med Klin (Munich) 94:431-42. 1999
    ..The authors give an overview of the current role of HDCT in lympho-hematopoietic malignancies and solid tumors...
  15. ncbi request reprint Fourth biannual report of the Cochrane Haematological Malignancies Group
    Thilo Kober
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 98:E1. 2006
  16. doi request reprint Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma
    Michaela Rancea
    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    J Natl Cancer Inst 105:1159-70. 2013
    ....
  17. ncbi request reprint A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgki
    Hans Theodor Eich
    Department of Radiation Oncology, University of Cologne, Cologne, Germany
    Int J Radiat Oncol Biol Phys 69:1187-92. 2007
    ..A quality control program based on a multidisciplinary panel of radiation oncologists, radiologists, and medical oncologists who reviewed all patients' staging and restaging imaging was initiated...
  18. ncbi request reprint Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group
    Karolin Behringer
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    J Clin Oncol 23:7555-64. 2005
    ..Among these, infertility for female patients is of major importance. The subject of this analysis is to evaluate the menstrual status after HL therapy...
  19. doi request reprint Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
    Bastian Von Tresckow
    University of Cologne, Cologne, Germany
    J Clin Oncol 30:907-13. 2012
    ..We aimed to improve these results using more intensive chemotherapy...
  20. ncbi request reprint Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group
    Andreas Josting
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    J Clin Oncol 23:1522-9. 2005
    ..To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated with salvage radiotherapy (SRT) alone...
  21. doi request reprint Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials
    Karolin Behringer
    University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 31:231-9. 2013
    ..To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy is needed. Therefore, we analyzed gonadal functions in survivors of HL...
  22. ncbi request reprint Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group
    Hans Theodor Eich
    Department of Radiation Oncology, University of Cologne, Cologne, Germany
    Int J Radiat Oncol Biol Phys 63:860-5. 2005
    ....
  23. doi request reprint Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
    Teresa V Halbsguth
    First Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Blood 116:2026-32. 2010
    ..Three patients died before response assessment. Thus, the BACOPP regimen is active in older HL patients but is compromised by a high rate of toxic deaths. This trial was registered at www.clinicaltrials.gov as #NCT00284271...
  24. doi request reprint Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma
    Kathrin Bauer
    Cochrane Haematological Malignancies Group, First Department of Internal Medicine, University Hospital of Cologne, Kerpener Strasse 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 102:E1. 2010
    ....
  25. ncbi request reprint Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymph
    Andreas Engert
    Department I of Internal Medicine, University Hospital Cologne, Cologne 50924, Germany
    J Clin Oncol 21:3601-8. 2003
    ..To investigate whether radiotherapy can be reduced without loss of efficacy from extended field (EF) to involved field (IF) after four cycles of chemotherapy...
  26. ncbi request reprint Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group
    Hans Theodor Eich
    Department of Radiation Oncology, University of Cologne, Cologne, Germany
    Int J Radiat Oncol Biol Phys 58:1121-7. 2004
    ..The purpose of the present investigation was to assess the feasibility of such a procedure and its impact on the final definition of disease extension and patient treatment...
  27. doi request reprint Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial
    Hans Theodor Eich
    University of Cologne, German Hodgkin Study Group, Koln, Germany
    J Clin Oncol 28:4199-206. 2010
    ..It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied...
  28. pmc Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
    Carsten Kobe
    Department of Nuclear Medicine, University of Cologne, Cologne, Germany
    Blood 112:3989-94. 2008
    ..Until then, response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials. This trial is registered at http://isrctn.org study as #ISRCTN32443041...
  29. doi request reprint Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis
    Nicole Skoetz
    Cochrane Haematological Malignancies Group, University Hospital of Cologne, Cologne, Germany
    Lancet Oncol 14:943-52. 2013
    ..To guide treatment decisions in this population of patients, we did a systematic review and network meta-analysis to identify the best initial treatment strategy...
  30. doi request reprint Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma
    Boris Boll
    Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Blood 118:6292-8. 2011
    ..We conclude that PVAG is safe and feasible in elderly HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00147875...
  31. ncbi request reprint Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Germany
    J Natl Cancer Inst 98:708-14. 2006
    ..08, 95% CI = 0.99 to 1.18; 42 trials and 8167 patients). Caution is advised when using epoetin or darbepoetin in combination with thrombogenic chemotherapeutic agents or for cancer patients who are at high risk for thrombo-embolic events...
  32. ncbi request reprint Current treatment and immunotherapy of Hodgkin's lymphoma
    Beate Klimm
    Department I of Internal Medicine, University Hospital Cologne, 50924 Cologne, Germany
    Haematologica 90:1680-92. 2005
    ..Radioimmunoconjugates and monoclonal antibodies have demonstrated some clinical efficacy. Here, we review new aspects in the treatment of primary and relapsed Hodgkin's lymphoma as well as recent immunotherapeutic approaches...
  33. ncbi request reprint Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
    Holger Schulz
    Department I of Internal Medicine, University of Cologne, Cologne, Germany
    Blood 111:109-11. 2008
    ..Thus, rituximab is highly effective in relapsed and refractory NLPHL. This study is registered at http://www.klinisches-studienzentrum.de/trial/285...
  34. ncbi request reprint Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5
    Markus Sieber
    German Hodgkin s Lymphoma Study Group, Cologne, Germany
    J Clin Oncol 20:476-84. 2002
    ....
  35. doi request reprint Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial o
    Peter Borchmann
    University Hospital of Cologne, Kerpener Str 62, 50924 Cologne, Germany
    J Clin Oncol 29:4234-42. 2011
    ..However, treatment-related toxicity is a concern, and the role of RT in this setting is unclear. The HD12 study thus aimed to reduce toxicity while maintaining efficacy...
  36. ncbi request reprint Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)
    Michal Sieniawski
    Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Blood 111:71-6. 2008
    ..Male patients with HL are at high risk of infertility after treatment with BEACOPP...
  37. doi request reprint Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors
    Nicole Skoetz
    Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    J Natl Cancer Inst 103:E1. 2011
    ....
  38. doi request reprint Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group
    Diana Wongso
    University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 31:2819-24. 2013
    ..However, this regimen has also been associated with higher treatment-related mortality (TRM). Thus, we analyzed clinical course and risk factors associated with TRM during treatment with BEACOPP(escalated)...
  39. doi request reprint ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials
    Boris Boll
    German Hodgkin Study Group, Cologne, Germany
    J Clin Oncol 31:1522-9. 2013
    ..ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is regarded as standard of care in these patients. However, little is known on feasibility and efficacy of ABVD in this age group...
  40. ncbi request reprint Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination o
    Henning Bredenfeld
    Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany
    J Clin Oncol 22:2424-9. 2004
    ....
  41. ncbi request reprint 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group
    M Sieber
    German Hodgkin s Lymphoma Study Group, Klinik fur Innere Medizin, University of Cologne, Germany
    J Clin Oncol 21:1734-9. 2003
    ....
  42. ncbi request reprint The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis
    Boris Boll
    University Hospital of Cologne, Department of Internal Medicine, Kerpener Str 62 D 50924 Köln, Germany
    Blood 106:1839-42. 2005
    ..We conclude that initial 5F11-mediated NF-kappaB signaling sensitizes the tumor cells to bortezomib-induced cell death. These data suggest a therapeutic value of this combination for HD patients...
  43. ncbi request reprint Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells
    Elke Pogge von Strandmann
    Department of Internal Medicine I, University Hospital of Cologne, Kerpener Str 62, D 50924 Cologne, Germany
    Immunity 27:965-74. 2007
    ..These data identify BAT3 as a cellular ligand for NKp30. We propose a concept for target cell recognition by NK cells beyond "missing self" and "induced self," mediated through a tumor cell-derived extracellular factor...
  44. ncbi request reprint Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
    Holger Schulz
    Cochrane Haematological Malignancies Group, Clinic I of Internal Medicine I, University of Cologne, Kerpenerstrasse 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 99:706-14. 2007
    ....
  45. ncbi request reprint Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group
    Lucia Nogova
    First Department of Internal Medicine, University Hospital Cologne, Kerpenerstr 62, 50924 Cologne, Germany
    J Clin Oncol 26:434-9. 2008
    ..To shed more light on the prognosis and outcome of LPHL, we reviewed all LPHL patients registered in the German Hodgkin Study Group (GHSG) database, comparing patient characteristics and treatment outcome with cHL patients...
  46. doi request reprint Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma
    Katrin S Reiners
    Laboratory of Immunotherapy, Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
    J Immunother 32:508-12. 2009
    ..On the basis of these results, a prospective clinical study has been initiated to further investigate the impact of this antiangiogenic approach in HL...
  47. ncbi request reprint Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
    B Klimm
    Department I of Internal Medicine, University Hospital Cologne, Germany
    Ann Oncol 18:357-63. 2007
    ..Since many of these patients receive combined modality treatment, we evaluated the impact of different radiation field sizes, that is extended-field (EF) or involved-field (IF) technique when given after four cycles of chemotherapy...
  48. doi request reprint Refractory Hodgkin lymphoma
    Bastian Von Tresckow
    Department I of Internal Medicine, University Hospital Cologne bGerman Hodgkin Study Group GHSG, Cologne, Germany
    Curr Opin Oncol 25:463-9. 2013
    ..Hodgkin Lymphoma can be refractory at first diagnosis or might become refractory later in the course of treatment. Both situations represent a therapeutic challenge...
  49. doi request reprint Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group
    Dennis A Eichenauer
    First Department of Internal Medicine, University Hospital of Cologne, Kerpener Str 62, 50924 Cologne, Germany
    J Clin Oncol 27:6079-85. 2009
    ..These data suggest that adult treatment protocols exhibit a safe and effective treatment option for adolescent patients with HL. However, longer follow-up, including assessment of late toxicity, is necessary for final conclusions...
  50. ncbi request reprint The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
    Peter Borchmann
    Klinik I für Innere Medizin der Universität Köln, Joseph Stelzmann Strasse 9, 50924 Cologne, Germany
    Blood 102:3737-42. 2003
    ..Based on these results, a clinical phase 1 study in patients with refractory CD30+ lymphoma has been initiated...
  51. doi request reprint Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma
    Roland Schnell
    Department I of Internal Medicine, University of Cologne, Germany
    Onkologie 31:49-51. 2008
    ..Thus, only very limited data of cHL patients treated with anti- CD20 immunoconstructs are available. To date, none of the patients treated with 90Y ibritumomab tiuxetan demonstrated any response...
  52. ncbi request reprint Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive mal
    Susanne Rödel
    Department I of Internal Medicine, University of Cologne, Germany
    Leuk Lymphoma 46:1729-34. 2005
    ..ACOMED followed by involved field radiation presents a highly effective regimen for remission induction and long-term survival in patients with aggressive NHL, and merits further investigation...
  53. ncbi request reprint A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
    Elke Pogge Von Strandmann
    Laboratory of Immunotherapy, Department I for Internal Medicine, University Hospital of Cologne, Kerpener Str 62, D 50924 Koln, Germany
    Blood 107:1955-62. 2006
    ..The use of recombinant NK receptor ligands that target NK cells to tumor cells might offer new approaches for other malignancies provided a tumor antigen-specific antibody is available...
  54. ncbi request reprint Third biannual report of the Cochrane Haematological Malignancies Group
    Thilo Kober
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 97:E2. 2005
  55. doi request reprint Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity
    Boris Boll
    Laboratory of Immunotherapy, Department of Hematology and Oncology, University Hospital Cologne, Cologne, Germany
    Clin Cancer Res 15:5108-16. 2009
    ..The molecular chaperone heat shock protein 90 (HSP90) has immune regulatory activity and supports the activation of NF-kappaB in Hodgkin's lymphoma cells...
  56. ncbi request reprint Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody
    Roland Schnell
    Department of Internal Medicine I, Department of Nuclear Medicine, University of Cologne, Germany
    J Clin Oncol 23:4669-78. 2005
    ..Thus, we developed a new radioimmunoconjugate consisting of the murine anti-CD30 monoclonal antibody (MAb) Ki-4 labeled with iodine-131 ((131)I)...
  57. ncbi request reprint Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial
    M Sieber
    Klinik I fur Innere Medizin, University of Cologne, Cologne, Germany
    Ann Oncol 15:276-82. 2004
    ....
  58. ncbi request reprint Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    J Natl Cancer Inst 97:489-98. 2005
    ..Anemia associated with cancer and cancer therapy is an important clinical and economic factor in the treatment of malignant diseases...
  59. doi request reprint Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group
    Beate Klimm
    University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 29:3914-20. 2011
    ..To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-depleted classical Hodgkin's lymphoma (LDCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL)...
  60. ncbi request reprint Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity
    Stefan Wilde
    Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
    Clin Pharmacokinet 46:319-33. 2007
    ..The present study was conducted to address the role of pharmacokinetics in individual toxicity...
  61. doi request reprint Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma
    Peter Borchmann
    Klinik I fur Innere Medizin, Universitat Koln, Koln, Germany
    Leuk Lymphoma 52:620-8. 2011
    ..Symptomatic cardiac failure occurred in four patients; however, pre-existing conditions confounded causality...
  62. ncbi request reprint A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
    V Ballova
    Department of Internal Medicine I, University Hospital of Cologne, Cologne and the German Hodgkin Lymphoma Study Group, Germany
    Ann Oncol 16:124-31. 2005
    ..Hodgkin-specific FFTF at 5 years was 55% after COPP-ABVD and 74% after BEACOPP (P=0.13). Thus, there are no differences in survival between these regimens in elderly patients...
  63. ncbi request reprint Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma
    Michal Sieniawski
    Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Ann Hematol 86:107-15. 2007
    ..However, only prospective randomized trial can offer sufficient data of the value of rituximab in relapsed and refractory aggressive NHL...
  64. ncbi request reprint Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial
    Thomas Elter
    Department of Hematology and Oncology, University of Cologne, Cologne, Germany
    J Clin Oncol 23:7024-31. 2005
    ..To determine the efficacy and safety of a newly developed concomitant administration of fludarabine and alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL)...
  65. pmc Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function
    Venkateswara Rao Simhadri
    Laboratory of Immune Therapy, Department of Internal Medicine I, Centre for Integrated Oncology Koeln Bonn, University of Cologne, Cologne, Germany
    PLoS ONE 3:e3377. 2008
    ..The manipulation of the exosomal regulation may offer a novel strategy to induce tumor immunity or inhibit autoimmune diseases caused by NK cell-activation...
  66. doi request reprint The role of PET in Hodgkin's lymphoma and its impact on radiation oncology
    Carsten Kobe
    Department of Nuclear Medicine, University Hospital of Cologne, Germany
    Expert Rev Anticancer Ther 10:1419-28. 2010
    ....
  67. doi request reprint Nodular lymphocyte-predominant Hodgkin's lymphoma
    Lucia Nogova
    First Department of Internal Medicine, University Hospital Cologne, Kerpenerstr 62, 50924 Cologne, Germany
    Curr Hematol Malig Rep 1:60-5. 2006
    ....
  68. ncbi request reprint Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
    Ute Rehwald
    Department I of Internal Medicine, University of Cologne, Germany
    Blood 101:420-4. 2003
    ..The median duration of response has not been reached yet (20+ months). We conclude that rituximab is both safe and effective in a subgroup of CD20(+) patients with HD...
  69. ncbi request reprint Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials
    Alexander Shimabukuro-Vornhagen
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    J Clin Oncol 23:5739-45. 2005
    ..To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-rich classical Hodgkin's lymphoma (LRCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL)...
  70. ncbi request reprint Fludarabine in chronic lymphocytic leukaemia
    Thomas Elter
    First Department of Internal Medicine, University of Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    Expert Opin Pharmacother 7:1641-51. 2006
    ....
  71. ncbi request reprint Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo
    Baerbel Matthey
    Medizinische Klinik I der Universitat zu Koln, Cologne, Germany
    Int J Cancer 111:568-74. 2004
    ..Thus, concomitant application of metalloproteinase inhibitors might become clinically relevant in antibody-based immunotherapy against targets known to be shed from tumor cells...
  72. ncbi request reprint The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imaging
    Hans Theodor Eich
    Department of Radiotherapy, University of Cologne, Germany
    Am J Clin Oncol 27:279-84. 2004
    ..Patients with Hodgkin disease receive high-quality CT imaging. A central independent multidisciplinary panel markedly improves quality assurance for these study patients...
  73. ncbi request reprint Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma
    Jan Peter Glossmann
    First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Ann Hematol 84:517-25. 2005
    ..Tandem HDCT followed by autologous stem cell transplantation (ASCT) offers a chance of cure in these poor prognostic patients, but is associated with risks...
  74. doi request reprint Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
    Andreas Josting
    University of Cologne, German Hodgkin Study Group, Koln, Germany
    J Clin Oncol 28:5074-80. 2010
    ..The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy...
  75. doi request reprint Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
    M Sieniawski
    Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Ann Oncol 19:1795-801. 2008
    ..Infertility is one of the most significant side-effects in long-term survivors of successfully treated Hodgkin's lymphoma (HL)...
  76. doi request reprint Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma
    Ron D Jachimowicz
    Department I of Internal Medicine, University Hospital Cologne, LFI, Ebene 4, Room 703, Kerpener Str 62, 50927 Cologne, Germany
    Mol Cancer Ther 10:1036-45. 2011
    ..Finally, the efficacy of a multimeric immunoligand is shown in a prostate carcinoma mouse xenograft model showing a strong activity against advanced established tumors...
  77. pmc Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review
    Christine Herbst
    Department I of Internal Medicine, Cochrane Haematological Malignancies Group CHMG, University Hospital Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
    Haematologica 95:494-500. 2010
    ..These trials underlined the results of the main analysis. In conclusion, adding radiotherapy to chemotherapy improves tumor control and OS in patients with early stage Hodgkin's lymphoma...
  78. doi request reprint Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy
    Christian Straka
    Schön Klinik Starnberger See, Berg, Germany, and Medizinische Klinik Innenstadt der Universität München, Munich, Germany
    Blood 117:2121-8. 2011
    ..0001). G-CSF responsiveness appears as a signature of the myeloid marrow reserve predicting defense against neutropenic infection after intensive chemotherapy. This study is registered at http://www.clinicaltrials.gov as NCT01085058...
  79. ncbi request reprint Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines
    Friederike Heuck
    Laboratory of Immunotherapy, Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany
    J Immunother 27:347-53. 2004
    ..The data suggest that the combination of the human antibody 5F11 with conventional chemotherapy might be beneficial in the combined chemo-immunotherapy of CD30-positive lymphomas...
  80. doi request reprint Combined modality treatment of Hodgkin's lymphoma
    Beate Klimm
    From the Department I of Internal Medicine and the German Hodgkin s Study Group GHSG, University Hospital Cologne, Germany
    Cancer J 15:143-9. 2009
    ..Here, we review results from current clinical trials and discuss new therapeutic approaches in the combined modality treatment of HL...
  81. doi request reprint Treatment of lymphocyte-predominant Hodgkin lymphoma
    A Engert
    Department of Internal Medicine 1, University of Cologne, Cologne, Germany
    Ann Oncol 19:iv45-6. 2008
  82. ncbi request reprint Depletion of cellular cholesterol and lipid rafts increases shedding of CD30
    Bastian Von Tresckow
    Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
    J Immunol 172:4324-31. 2004
    ..Our results suggest a possible role of cholesterol-dependent shedding of CD30 in the pathogenesis of immune diseases...
  83. ncbi request reprint Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
    Beate Klimm
    First Department of Internal Medicine, University Hospital Cologne, Germany
    J Clin Oncol 23:8003-11. 2005
    ..We systematically investigated sex differences with regard to pretreatment characteristics and therapy-related variables, and examined their influence on the outcome of HL patients...
  84. ncbi request reprint Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma
    Olaf Weingart
    Cochrane Haematological Malignancies Group Department of Internal Medicine 1, University Hospital of Cologne, Kerpener Street 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 99:E1. 2007
  85. ncbi request reprint Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo
    Bastian Von Tresckow
    Laboratory of Immunotherapy, Clinic I of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Haematologica 92:682-5. 2007
    ..Since the prenylation-inhibitors FTI-277 and GGTI-298 were also effective against HL-cells, we conclude that statins and specific prenylation-inhibitors should be evaluated in HL patients...
  86. ncbi request reprint New strategies for the treatment of advanced-stage Hodgkin's lymphoma
    Volker Diehl
    Department of Internal Medicine I, Haus Lebenswert, University Hospital of Cologne, Kerpenerstr 62, 50931 Cologne, Germany
    Hematol Oncol Clin North Am 21:897-914. 2007
    ..With this individualized approach it might be possible to yield higher cure rates and simultaneously reduce the risk for late complications and mortality...
  87. ncbi request reprint A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseas
    J P Glossmann
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50931 Cologne, Germany
    Ann Hematol 81:424-9. 2002
  88. ncbi request reprint An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
    J Boye
    Clinic I of Internal Medicine, University Hospital of Cologne, Germany
    Ann Oncol 14:520-35. 2003
    ..The monoclonal antibody is generally well tolerated. Most adverse events are infusion-associated, including chills, fever and rigor related to the release of cytokines...
  89. ncbi request reprint A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma
    Roland Schnell
    Department of Internal Medicine I, University of Koeln, Joseph Stelzmann Strasse 9, D 50924 Koeln, Germany
    Clin Cancer Res 8:1779-86. 2002
    ..This might be because of the low number of CD30+ peripheral blood mononuclear cells, and in part because of binding of the IT to soluble CD30 antigen and the resulting circulation of IT/sCD30 complexes...
  90. ncbi request reprint Current strategies of antibody-based treatment in Hodgkin's disease
    R Schnell
    Klinik I fur Innere Medizin, Universitat zu Koln, Germany
    Ann Oncol 13:57-66. 2002
    ..Future phase III trials will have to prove a possible superior effect of this combined immunochemotherapy. Currently, the evaluation of the most promising approaches continues...
  91. ncbi request reprint Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
    Holger Schulz
    Clinic I of Internal Medicine, University of Cologne, Cologne 50924, Germany
    Blood 100:3115-20. 2002
    ..The median duration of response was 75 weeks. We conclude that the combination of rituximab and fludarabine is feasible and effective in patients with B-CLL...
  92. pmc Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning
    A Klimka
    Department of Internal Medicine I, University Hospital Cologne, Germany
    Br J Cancer 83:252-60. 2000
    ....
  93. ncbi request reprint High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis
    Alexander Greb
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    Cancer Treat Rev 33:338-46. 2007
    ..Randomized controlled trials (RCTs) reported conflicting results on the impact of high-dose chemotherapy (HDCT) and autologous stem cell transplantation in the first-line treatment of patients with aggressive non-Hodgkin lymphoma (NHL)...
  94. doi request reprint Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia
    Christine Herbst
    Department of Internal Medicine 1, Cochrane Haematological Malignancies Group, University Hospital of Cologne, Cologne, Germany
    J Natl Cancer Inst 100:E1. 2008
  95. pmc An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line
    A Klimka
    Department of Internal Medicine I, University Hospital Cologne, Germany
    Br J Cancer 80:1214-22. 1999
    ..This recombinant immunotoxin is a promising candidate for further clinical evaluation in patients with Hodgkin's lymphoma or other CD30+ malignancies...
  96. ncbi request reprint Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
    B Coiffier
    Service d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite, France the Service d Hématologie, Hopital Henri Mondor, Creteil, France the Klinik 1 fur Innere Medezin, Universitat zu Koln, Koln, Germany
    Blood 92:1927-32. 1998
    ..Rituximab has significant activity in DLCL and MCL patients and should be tested in combination with chemotherapy in such patients...
  97. ncbi request reprint Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab
    H Pels
    Clinic I for Internal Medicine, University of Cologne, Germany
    J Neurooncol 59:213-6. 2002
    ..Efficacy and pharmacokinetics of rituximab in PCNSL should be investigated in future trials...
  98. ncbi request reprint New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group
    Andreas Josting
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelman Strasse 9, 50924 Cologne, Germany
    J Clin Oncol 20:221-30. 2002
    ..To evaluate salvage treatment outcome of patients with relapsed Hodgkin's disease (HD) and to distinguish different risk groups using identified prognostic factors...
  99. ncbi request reprint Second biannual report of the Cochrane Haematological Malignancies Group
    Thilo Kober
    Cochrane Haematological Malignancies Group, Cologne, Germany
    J Natl Cancer Inst 97:E1. 2005
  100. ncbi request reprint Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
    Markus Jensen
    University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
    Invest New Drugs 26:139-49. 2008
    ..Further study of R-etodolac as a possible new maintenance therapy or as a part of combination therapy of B-CLL appears warranted...
  101. ncbi request reprint A consumer network for haematological malignancies
    Nicole Skoetz
    Cochrane Haematological Malignancies Group, First Department of Internal Medicine, University of Cologne, Koln, Germany
    Health Expect 8:86-90. 2005